Support Burnet’s COVID-19 emergency response
COVID-19 represents an unprecedented health, social and economic challenge in Australia and around the world. Support Burnet’s COVID-19 emergency response today.
COVID-19 represents an unprecedented health, social and economic challenge in Australia and around the world. Support Burnet’s COVID-19 emergency response today.
Our overall aim is to characterise new drug scaffolds and their novel binding sites on HIV reverse transcriptase to advance fundamental understanding of reverse transcriptase structure and function and to underpin the discovery of a new HIV drug class.
This new drug class is aimed to have a distinct mechanism of action and resistance profile to drugs currently used for HIV treatment and prevention
2017 – 2019
Associate Professor David Chalmers Professor Nicolas Sluis-Cremer Professor Eddy Arnold Associate Professor Philip Thompson Dr Stephen Headey Dr Catherine Latham Dr Joseph Bauman Professor Martin Scanlon Professor Susan Charman
NHMRC
For any general enquiries relating to this project, please contact:
Head of Life Sciences; Head of Tachedjian Laboratory (Retroviral Biology and Antivirals)
To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2020 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung and Wurundjeri people and we offer our respects to the elders past and present.
We recognise and respect the cultural heritage of this land.
